A phase 1b study of glasdegib + azacitidine in patients with untreated acute myeloid leukemia and higher-risk myelodysplastic syndromes by Sekeres, MA, Schuster, M, Joris, M, Krauter, J, Maertens, J, Breems, D, Gyan, E, Kovacsovics, T, Verma, A, Vyas, P, Wang, ES, Ching, K, O'Brien, T, Gallo Stampino, C, Ma, WW, Kudla, A, Chan, G, Zeidan, AM

Molecular remission and response patterns in patients with mutant-IDH2 acute myeloid leukemia treated with enasidenib by Stein, EM, Dinardo, CD, Fathi, AT, Pollyea, DA, Stone, RM, Altman, JK, Roboz, GJ, Patel, MR, Collins, R, Flinn, IW, Sekeres, MA, Stein, AS, Kantarjian, HM, Levine, RL, Vyas, P, Macbeth, KJ, Tosolini, A, Vanoostendorp, J, Xu, Q, Gupta, I, Lila, T, Risueno, A, Yen, KE, Wu, B, Attar, EC, Tallman, MS, De Botton, S

Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia by Stein, EM, DiNardo, CD, Pollyea, DA, Fathi, AT, Roboz, GJ, Altman, JK, Stone, RM, DeAngelo, DJ, Levine, RL, Flinn, IW, Kantarjian, HM, Collins, R, Patel, MR, Frankel, AE, Stein, A, Sekeres, MA, Swords, RT, Medeiros, BC, Willekens, C, Vyas, P, Tosolini, A, Xu, Q, Knight, RD, Yen, KE, Agresta, S, De Botton, S, Tallman, MS

Luspatercept in patients with lower-risk myelodysplastic syndromes by Fenaux, P, Platzbecker, U, Mufti, GJ, Garcia-Manero, G, Buckstein, R, Santini, V, Díez-Campelo, M, Finelli, C, Cazzola, M, Ilhan, O, Sekeres, MA, Falantes, JF, Arrizabalaga, B, Salvi, F, Giai, V, Vyas, P, Bowen, D, Selleslag, D, DeZern, AE, Jurcic, JG, Germing, U, Götze, KS, Quesnel, B, Beyne-Rauzy, O, Cluzeau, T, Voso, M-T, Mazure, D, Vellenga, E, Greenberg, PL, Hellström-Lindberg, E, Zeidan, AM, Adès, L, Verma, A, Savona, MR, Laadem, A, Benzohra, A, Zhang, J, Rampersad, A, Dunshee, DR, Linde, PG, Sherman, ML, Komrokji, RS, List, AF

Classification, risk stratification and response assessment in myelodysplastic syndromes/neoplasms (MDS): a state-of-the-art report on behalf of the International Consortium for MD... by Stahl, M, Bewersdorf, JP, Xie, Z, Porta, MGD, Komrokji, R, Xu, ML, Abdel-Wahab, O, Taylor, J, Steensma, DP, Starczynowski, DT, Sekeres, MA, Sanz, G, Sallman, DA, Roboz, GJ, Platzbecker, U, Patnaik, MM, Padron, E, Odenike, O, Nimer, SD, Nazha, A, Majeti, R, Loghavi, S, Little, RF, List, AF, Kim, TK, Hourigan, CS, Hasserjian, RP, Halene, S, Griffiths, EA, Gore, SD, Greenberg, P, Figueroa, ME, Fenaux, P, Efficace, F, DeZern, AE, Daver, NG, Churpek, JE, Carraway, HE, Buckstein, R, Brunner, AM, Boultwood, J, Borate, U, Bejar, R, Bennett, JM, Wei, AH, Santini, V, Savona, MR, Zeidan, AM

Special considerations in the management of adult patients with acute leukaemias and myeloid neoplasms in the COVID-19 era: recommendations from a panel of international experts by Zeidan, AM, Boddu, PC, Patnaik, MM, Bewersdorf, JP, Stahl, M, Rampal, RK, Shallis, R, Steensma, DP, Savona, MR, Sekeres, MA, Roboz, GJ, DeAngelo, DJ, Schuh, AC, Padron, E, Zeidner, JF, Walter, RB, Onida, F, Fathi, A, DeZern, A, Hobbs, G, Stein, EM, Vyas, P, Wei, AH, Bowen, DT, Montesinos, P, Griffiths, EA, Verma, AK, Keyzner, A, Bar-Natan, M, Navada, SC, Kremyanskaya, M, Goldberg, AD, Al-Kali, A, Heaney, ML, Nazha, A, Salman, H, Luger, S, Pratz, KW, Konig, H, Komrokji, R, Deininger, M, Cirici, BX, Bhatt, VR, Silverman, LR, Erba, HP, Fenaux, P, Platzbecker, U, Santini, V, Wang, ES, Tallman, MS

TP53 mutation status divides myelodysplastic syndromes with complex karyotypes into distinct prognostic subgroups by Haase, D, Stevenson, KE, Neuberg, D, Maciejewski, JP, Nazha, A, Sekeres, MA, Ebert, BL, Garcia-Manero, G, Haferlach, C, Haferlach, T, Kern, W, Ogawa, S, Nagata, Y, Yoshida, K, Graubert, TA, Walter, MJ, List, AF, Komrokji, RS, Padron, E, Sallman, D, Papaemmanuil, E, Campbell, PJ, Savona, MR, Seegmiller, A, Adès, L, Fenaux, P, Shih, L-Y, Bowen, D, Groves, MJ, Tauro, S, Fontenay, M, Kosmider, O, Bar-Natan, M, Steensma, D, Stone, R, Heuser, M, Thol, F, Cazzola, M, Malcovati, L, Karsan, A, Ganster, C, Hellström-Lindberg, E, Boultwood, J, Pellagatti, A, Santini, V, Quek, L, Vyas, P, Tüchler, H, Greenberg, PL, Bejar, R, International Working Group For Mds Molecular Prognostic Committee